When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Disclaimer Statement: This content is authored by a 3rd party. The views expressed here are that of the respective authors/ entities and do not represent the views of Economic Times (ET). ET does not ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in ...

“Yeah, my dad went viral for these cutaway shots during yesterday’s broadcast. The internet’s obsessed with this little smile and goofy expression.” The next four years will change America forever.

Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01 ...

Oculis plans to evaluate OCS-05 to treat other pervasive ophthalmologic neurological pathological disorders, such as geographic atrophy, neuropathic keratitis, and glaucoma.

But a window has been opened for acknowledging that, as a matter of law, protecting human expression is qualitatively different from enabling algorithmic manipulation of human attention.

Another buzzy new show on Paramount+ is Dexter: Original Sin. The prequel to Showtime’s game-changing action thriller Dexter is, sadly, taking a week off. When exactly does Dexter: Original Sin ...